J&J-Pharmacyclics Breakthrough Drug Wins U.S. Approval

Johnson & Johnson and Pharmacyclics Inc. won U.S. approval for their breakthrough therapy to treat a rare blood cancer, becoming the second drug to gain marketing clearance under the process created to speed new medicines to seriously ill patients.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.